Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > 64.5 million traded at 3.5 cents average

<< Previous

Bullboard Posts

Next >>

Comment by Walterthedogon Dec 29, 2020 6:26pm

207 Views

Post# 32194038

RE:RE:RE:RE:RE:64.5 million traded at 3.5 cents average

That's where my thinking is at. It was only this low because of the giant mess that current management has now put behind them. If midpoint data confirms efficacy, I expect there will be a lot more interest in the stock. Im setting a sell for 1.80$ tomorrow and with some good news and luck, we will hit that sometime in 2021.

<< Previous

Bullboard Posts

Next >>

Globex Mining: Unveiling Québec’s hidden gold and lithium treasures